Study on Monitoring Imatinib Levels in Patients with Gastrointestinal Stromal Tumors (GIST)

Sponsor: Reema A. Patel

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT05493215

Provider View

This clinical trial is exploring how monitoring the levels of the drug Imatinib in the blood can help improve the quality of life for patients with gastrointestinal stromal tumors (GIST) by managing side effects and ensuring effective treatment.

Patient Parameters

Program Overview

Imatinib is a medication that can help patients with gastrointestinal stromal tumors (GIST) live longer without the cancer coming back. However, it can also cause side effects that affect patients' quality of life. This study aims to use therapeutic drug monitoring to help manage these side effects and ensure that patients maintain the right levels of the drug in their system. Researchers will also look at how the drug moves and is processed in the body.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of gastrointestinal stromal tumors (GIST) with specific genetic mutations (KIT or PDGFRA, but not D842V).
  • Currently taking Imatinib, started within the last 3 months or planning to start within the next month.
  • Have completed any previous chemotherapy for other cancers at least 6 months ago, with no signs of disease.
  • Be 18 years or older.
  • Be in good overall health, with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
  • Have normal organ function as determined by medical tests.

Exclusion Criteria

  • Have a specific PDGFRA D842V mutation.
  • Have a known allergy to Imatinib or similar drugs.
  • Currently taking the blood thinner warfarin.
  • Using certain medications that affect how Imatinib is processed in the body.
  • Have any uncontrolled illnesses.
  • Have another active cancer.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.